Endovascular Engineering, which goes by E2, closed an oversubscribed $80M Series C on April 7, 2026. Gilde Healthcare and Norwest co-led. Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners and M&L Healthcare Investments joined, along with two existing strategic investors and one new global strategic. Geoff Pardo of Gilde and Zack Scott of Norwest take board seats.
FDA cleared the Hēlo Thrombectomy System under K252956 on December 18, 2025, 93 days after receipt. The clearance sits under 21 CFR 870.5150, product code QEW, peripheral mechanical thrombectomy with aspiration. The labeled indication is non-surgical removal of emboli and thrombi from pulmonary arteries and venous vasculature. The catheter pairs aspiration with mechanical clot disruption in a small-profile device meant for single-pass procedures.
CEO Dan Rose said the money builds a commercial organization while funding R&D and operations. E2 cleared an earlier device, the Cobra Catheter System, under K223891 in February 2023. Two 510(k)s in three years and an $80M commercial round is a quick path from bench to sales team.